Review



plasma pcsk9 protein levels  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    R&D Systems plasma pcsk9 protein levels
    (A) Top: Schematic of experiments demonstrating delivery of AAV-Myd88 or Mock repressors to Cas9 nuclease transgenic mice; Bottom: Analysis of anti-AAV1 IgG2A antibody by ELISA. Optical density values are quantified relative to the AAV1/Mock group (N=8 mice). (B) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV1/Mock on day 21; Bottom: Anti-AAV1 IgG1 and total IgG antibody measured by ELISA at different time points. Optical density values are quantified relative to a value of AAV1/Mock+AAV1/Mock group (N=4 mice). (C) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/SaCas9 on day 21; Bottom: Analysis of Anti-AAV9 IgG and Anti Sa-Cas9 levels in mice sera. Optical density values are quantified relative to the AAV1/Mock+AAV9/SaCas9 group (N=4 mice). (D) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/LacZ on day 21; Bottom: Analysis of Anti-AAV9 IgG in mice sera and LacZ mRNA levels in blood. Relative optical density values are quantified relative to the AAV1/Mock+AAV9/LacZ group (N=4 mice). (E) Top: Schematic of the experiment. Cas9 nuclease transgenic mice were treated with AAV1/Myd88 or AAV1/Mock vectors via retro-orbital injection followed by a second and third injection of <t>AAV9/PCSK9</t> vectors on day 7 and 21. (F) Analysis of anti-AAV9 IgG and total IgG antibody measured by ELISA. Optical density values are quantified relative to the AAV1/Mock+AAV9/PCSK9+AAV9/PCSK9 group (N=4 mice). (G and H) Plasma samples collected from treated animals were assayed for (G) PCSK9 and (H) Cholesterol at days 0, 7, 21, and 30 (N=4 mice). Panel A-H data are expressed as mean + S.E.M. (Mock= Mock-HP1aKRAB, Myd88= Myd88-HP1aKRAB, PCSK9= PCSK9-HP1aKRAB). Statistical analyses were performed using the non-parametric one-tailed Mann-Whitney U test. A p value ≤ 0.05 was considered significant (*p ≤ 0.05, and ****p ≤ 0.0001). Statistical source data are provided in .
    Plasma Pcsk9 Protein Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 81 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasma+pcsk9+protein+levels/Mouse+Proprotein+Convertase+9%2FPCSK9+Quantikine+ELISA+Kit/pmc07480217-158-0-13
    Average 95 stars, based on 81 article reviews
    plasma pcsk9 protein levels - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "Synthetic immunomodulation with a CRISPR super-repressor in vivo"

    Article Title: Synthetic immunomodulation with a CRISPR super-repressor in vivo

    Journal: Nature cell biology

    doi: 10.1038/s41556-020-0563-3

    (A) Top: Schematic of experiments demonstrating delivery of AAV-Myd88 or Mock repressors to Cas9 nuclease transgenic mice; Bottom: Analysis of anti-AAV1 IgG2A antibody by ELISA. Optical density values are quantified relative to the AAV1/Mock group (N=8 mice). (B) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV1/Mock on day 21; Bottom: Anti-AAV1 IgG1 and total IgG antibody measured by ELISA at different time points. Optical density values are quantified relative to a value of AAV1/Mock+AAV1/Mock group (N=4 mice). (C) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/SaCas9 on day 21; Bottom: Analysis of Anti-AAV9 IgG and Anti Sa-Cas9 levels in mice sera. Optical density values are quantified relative to the AAV1/Mock+AAV9/SaCas9 group (N=4 mice). (D) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/LacZ on day 21; Bottom: Analysis of Anti-AAV9 IgG in mice sera and LacZ mRNA levels in blood. Relative optical density values are quantified relative to the AAV1/Mock+AAV9/LacZ group (N=4 mice). (E) Top: Schematic of the experiment. Cas9 nuclease transgenic mice were treated with AAV1/Myd88 or AAV1/Mock vectors via retro-orbital injection followed by a second and third injection of AAV9/PCSK9 vectors on day 7 and 21. (F) Analysis of anti-AAV9 IgG and total IgG antibody measured by ELISA. Optical density values are quantified relative to the AAV1/Mock+AAV9/PCSK9+AAV9/PCSK9 group (N=4 mice). (G and H) Plasma samples collected from treated animals were assayed for (G) PCSK9 and (H) Cholesterol at days 0, 7, 21, and 30 (N=4 mice). Panel A-H data are expressed as mean + S.E.M. (Mock= Mock-HP1aKRAB, Myd88= Myd88-HP1aKRAB, PCSK9= PCSK9-HP1aKRAB). Statistical analyses were performed using the non-parametric one-tailed Mann-Whitney U test. A p value ≤ 0.05 was considered significant (*p ≤ 0.05, and ****p ≤ 0.0001). Statistical source data are provided in .
    Figure Legend Snippet: (A) Top: Schematic of experiments demonstrating delivery of AAV-Myd88 or Mock repressors to Cas9 nuclease transgenic mice; Bottom: Analysis of anti-AAV1 IgG2A antibody by ELISA. Optical density values are quantified relative to the AAV1/Mock group (N=8 mice). (B) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV1/Mock on day 21; Bottom: Anti-AAV1 IgG1 and total IgG antibody measured by ELISA at different time points. Optical density values are quantified relative to a value of AAV1/Mock+AAV1/Mock group (N=4 mice). (C) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/SaCas9 on day 21; Bottom: Analysis of Anti-AAV9 IgG and Anti Sa-Cas9 levels in mice sera. Optical density values are quantified relative to the AAV1/Mock+AAV9/SaCas9 group (N=4 mice). (D) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/LacZ on day 21; Bottom: Analysis of Anti-AAV9 IgG in mice sera and LacZ mRNA levels in blood. Relative optical density values are quantified relative to the AAV1/Mock+AAV9/LacZ group (N=4 mice). (E) Top: Schematic of the experiment. Cas9 nuclease transgenic mice were treated with AAV1/Myd88 or AAV1/Mock vectors via retro-orbital injection followed by a second and third injection of AAV9/PCSK9 vectors on day 7 and 21. (F) Analysis of anti-AAV9 IgG and total IgG antibody measured by ELISA. Optical density values are quantified relative to the AAV1/Mock+AAV9/PCSK9+AAV9/PCSK9 group (N=4 mice). (G and H) Plasma samples collected from treated animals were assayed for (G) PCSK9 and (H) Cholesterol at days 0, 7, 21, and 30 (N=4 mice). Panel A-H data are expressed as mean + S.E.M. (Mock= Mock-HP1aKRAB, Myd88= Myd88-HP1aKRAB, PCSK9= PCSK9-HP1aKRAB). Statistical analyses were performed using the non-parametric one-tailed Mann-Whitney U test. A p value ≤ 0.05 was considered significant (*p ≤ 0.05, and ****p ≤ 0.0001). Statistical source data are provided in .

    Techniques Used: Transgenic Assay, Enzyme-linked Immunosorbent Assay, Injection, Clinical Proteomics, One-tailed Test, MANN-WHITNEY

    (A) Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV1/Mock on day 21. (B) qRT-PCR analysis of Myd88 expression level in lung, blood, and bone marrow of Cas9 transgenic mice (N = 4 mice). Fold changes are relative to universal control. The bars represent the mean + S.E.M. (C) Schematic of the experiment. Cas9 nuclease transgenic mice were treated with AAV1-Myd88 or AAV1-Mock vectors via retro-orbital injection followed by a second and third injection of AAV9-PCSK9 vectors on day 7 and 21. (D) qRT-PCR analysis of Myd88 expression level in lung, blood, and bone marrow of Cas9 transgenic mice (N = 4 mice). The bars represent the mean + S.E.M. (Mock= Mock-HP1aKRAB, Myd88= Myd88-HP1aKRAB, PCSK9= PCSK9-HP1aKRAB). Fold changes are relative to universal control. Universal control is a blood sample collected from an uninjected Cas9 transgenic mouse. Statistical analysis was performed using the non-parametric one-tailed Mann-Whitney U test. A p value ≤ 0.05 was considered significant (*P ≤ 0.05). Statistical source data are provided in .
    Figure Legend Snippet: (A) Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV1/Mock on day 21. (B) qRT-PCR analysis of Myd88 expression level in lung, blood, and bone marrow of Cas9 transgenic mice (N = 4 mice). Fold changes are relative to universal control. The bars represent the mean + S.E.M. (C) Schematic of the experiment. Cas9 nuclease transgenic mice were treated with AAV1-Myd88 or AAV1-Mock vectors via retro-orbital injection followed by a second and third injection of AAV9-PCSK9 vectors on day 7 and 21. (D) qRT-PCR analysis of Myd88 expression level in lung, blood, and bone marrow of Cas9 transgenic mice (N = 4 mice). The bars represent the mean + S.E.M. (Mock= Mock-HP1aKRAB, Myd88= Myd88-HP1aKRAB, PCSK9= PCSK9-HP1aKRAB). Fold changes are relative to universal control. Universal control is a blood sample collected from an uninjected Cas9 transgenic mouse. Statistical analysis was performed using the non-parametric one-tailed Mann-Whitney U test. A p value ≤ 0.05 was considered significant (*P ≤ 0.05). Statistical source data are provided in .

    Techniques Used: Transgenic Assay, Quantitative RT-PCR, Expressing, Control, Injection, One-tailed Test, MANN-WHITNEY

    Related Articles

    Clinical Proteomics:

    Article Title: Synthetic immunomodulation with a CRISPR super-repressor in vivo
    Article Snippet: Plasma levels of cholesterol were measured via a colorimetric assay according to the manufacturer’s instructions (Thermo- Scientific Total Cholesterol Reagents #TR13421). .. Plasma Pcsk9 protein levels were quantified by ELISA according to the manufacturer’s instructions (R&D Systems #MPC900). .. Lung samples were lysed using 1× cell lysis buffer (Cell Signaling) (ratio of 100 mg of tissue to 1 ml of buffer) followed by homogenization and sonication of the lysed tissue.

    Enzyme-linked Immunosorbent Assay:

    Article Title: Synthetic immunomodulation with a CRISPR super-repressor in vivo
    Article Snippet: Plasma levels of cholesterol were measured via a colorimetric assay according to the manufacturer’s instructions (Thermo- Scientific Total Cholesterol Reagents #TR13421). .. Plasma Pcsk9 protein levels were quantified by ELISA according to the manufacturer’s instructions (R&D Systems #MPC900). .. Lung samples were lysed using 1× cell lysis buffer (Cell Signaling) (ratio of 100 mg of tissue to 1 ml of buffer) followed by homogenization and sonication of the lysed tissue.



    Similar Products

    plasma pcsk9 protein levels  (R&D Systems)
    95
    R&D Systems plasma pcsk9 protein levels
    (A) Top: Schematic of experiments demonstrating delivery of AAV-Myd88 or Mock repressors to Cas9 nuclease transgenic mice; Bottom: Analysis of anti-AAV1 IgG2A antibody by ELISA. Optical density values are quantified relative to the AAV1/Mock group (N=8 mice). (B) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV1/Mock on day 21; Bottom: Anti-AAV1 IgG1 and total IgG antibody measured by ELISA at different time points. Optical density values are quantified relative to a value of AAV1/Mock+AAV1/Mock group (N=4 mice). (C) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/SaCas9 on day 21; Bottom: Analysis of Anti-AAV9 IgG and Anti Sa-Cas9 levels in mice sera. Optical density values are quantified relative to the AAV1/Mock+AAV9/SaCas9 group (N=4 mice). (D) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/LacZ on day 21; Bottom: Analysis of Anti-AAV9 IgG in mice sera and LacZ mRNA levels in blood. Relative optical density values are quantified relative to the AAV1/Mock+AAV9/LacZ group (N=4 mice). (E) Top: Schematic of the experiment. Cas9 nuclease transgenic mice were treated with AAV1/Myd88 or AAV1/Mock vectors via retro-orbital injection followed by a second and third injection of <t>AAV9/PCSK9</t> vectors on day 7 and 21. (F) Analysis of anti-AAV9 IgG and total IgG antibody measured by ELISA. Optical density values are quantified relative to the AAV1/Mock+AAV9/PCSK9+AAV9/PCSK9 group (N=4 mice). (G and H) Plasma samples collected from treated animals were assayed for (G) PCSK9 and (H) Cholesterol at days 0, 7, 21, and 30 (N=4 mice). Panel A-H data are expressed as mean + S.E.M. (Mock= Mock-HP1aKRAB, Myd88= Myd88-HP1aKRAB, PCSK9= PCSK9-HP1aKRAB). Statistical analyses were performed using the non-parametric one-tailed Mann-Whitney U test. A p value ≤ 0.05 was considered significant (*p ≤ 0.05, and ****p ≤ 0.0001). Statistical source data are provided in .
    Plasma Pcsk9 Protein Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasma+pcsk9+protein+levels/Mouse+Proprotein+Convertase+9%2FPCSK9+Quantikine+ELISA+Kit/pmc07480217-158-0-13
    Average 95 stars, based on 1 article reviews
    plasma pcsk9 protein levels - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Top: Schematic of experiments demonstrating delivery of AAV-Myd88 or Mock repressors to Cas9 nuclease transgenic mice; Bottom: Analysis of anti-AAV1 IgG2A antibody by ELISA. Optical density values are quantified relative to the AAV1/Mock group (N=8 mice). (B) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV1/Mock on day 21; Bottom: Anti-AAV1 IgG1 and total IgG antibody measured by ELISA at different time points. Optical density values are quantified relative to a value of AAV1/Mock+AAV1/Mock group (N=4 mice). (C) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/SaCas9 on day 21; Bottom: Analysis of Anti-AAV9 IgG and Anti Sa-Cas9 levels in mice sera. Optical density values are quantified relative to the AAV1/Mock+AAV9/SaCas9 group (N=4 mice). (D) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/LacZ on day 21; Bottom: Analysis of Anti-AAV9 IgG in mice sera and LacZ mRNA levels in blood. Relative optical density values are quantified relative to the AAV1/Mock+AAV9/LacZ group (N=4 mice). (E) Top: Schematic of the experiment. Cas9 nuclease transgenic mice were treated with AAV1/Myd88 or AAV1/Mock vectors via retro-orbital injection followed by a second and third injection of AAV9/PCSK9 vectors on day 7 and 21. (F) Analysis of anti-AAV9 IgG and total IgG antibody measured by ELISA. Optical density values are quantified relative to the AAV1/Mock+AAV9/PCSK9+AAV9/PCSK9 group (N=4 mice). (G and H) Plasma samples collected from treated animals were assayed for (G) PCSK9 and (H) Cholesterol at days 0, 7, 21, and 30 (N=4 mice). Panel A-H data are expressed as mean + S.E.M. (Mock= Mock-HP1aKRAB, Myd88= Myd88-HP1aKRAB, PCSK9= PCSK9-HP1aKRAB). Statistical analyses were performed using the non-parametric one-tailed Mann-Whitney U test. A p value ≤ 0.05 was considered significant (*p ≤ 0.05, and ****p ≤ 0.0001). Statistical source data are provided in .

    Journal: Nature cell biology

    Article Title: Synthetic immunomodulation with a CRISPR super-repressor in vivo

    doi: 10.1038/s41556-020-0563-3

    Figure Lengend Snippet: (A) Top: Schematic of experiments demonstrating delivery of AAV-Myd88 or Mock repressors to Cas9 nuclease transgenic mice; Bottom: Analysis of anti-AAV1 IgG2A antibody by ELISA. Optical density values are quantified relative to the AAV1/Mock group (N=8 mice). (B) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV1/Mock on day 21; Bottom: Anti-AAV1 IgG1 and total IgG antibody measured by ELISA at different time points. Optical density values are quantified relative to a value of AAV1/Mock+AAV1/Mock group (N=4 mice). (C) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/SaCas9 on day 21; Bottom: Analysis of Anti-AAV9 IgG and Anti Sa-Cas9 levels in mice sera. Optical density values are quantified relative to the AAV1/Mock+AAV9/SaCas9 group (N=4 mice). (D) Top: Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV9/LacZ on day 21; Bottom: Analysis of Anti-AAV9 IgG in mice sera and LacZ mRNA levels in blood. Relative optical density values are quantified relative to the AAV1/Mock+AAV9/LacZ group (N=4 mice). (E) Top: Schematic of the experiment. Cas9 nuclease transgenic mice were treated with AAV1/Myd88 or AAV1/Mock vectors via retro-orbital injection followed by a second and third injection of AAV9/PCSK9 vectors on day 7 and 21. (F) Analysis of anti-AAV9 IgG and total IgG antibody measured by ELISA. Optical density values are quantified relative to the AAV1/Mock+AAV9/PCSK9+AAV9/PCSK9 group (N=4 mice). (G and H) Plasma samples collected from treated animals were assayed for (G) PCSK9 and (H) Cholesterol at days 0, 7, 21, and 30 (N=4 mice). Panel A-H data are expressed as mean + S.E.M. (Mock= Mock-HP1aKRAB, Myd88= Myd88-HP1aKRAB, PCSK9= PCSK9-HP1aKRAB). Statistical analyses were performed using the non-parametric one-tailed Mann-Whitney U test. A p value ≤ 0.05 was considered significant (*p ≤ 0.05, and ****p ≤ 0.0001). Statistical source data are provided in .

    Article Snippet: Plasma Pcsk9 protein levels were quantified by ELISA according to the manufacturer’s instructions (R&D Systems #MPC900).

    Techniques: Transgenic Assay, Enzyme-linked Immunosorbent Assay, Injection, Clinical Proteomics, One-tailed Test, MANN-WHITNEY

    (A) Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV1/Mock on day 21. (B) qRT-PCR analysis of Myd88 expression level in lung, blood, and bone marrow of Cas9 transgenic mice (N = 4 mice). Fold changes are relative to universal control. The bars represent the mean + S.E.M. (C) Schematic of the experiment. Cas9 nuclease transgenic mice were treated with AAV1-Myd88 or AAV1-Mock vectors via retro-orbital injection followed by a second and third injection of AAV9-PCSK9 vectors on day 7 and 21. (D) qRT-PCR analysis of Myd88 expression level in lung, blood, and bone marrow of Cas9 transgenic mice (N = 4 mice). The bars represent the mean + S.E.M. (Mock= Mock-HP1aKRAB, Myd88= Myd88-HP1aKRAB, PCSK9= PCSK9-HP1aKRAB). Fold changes are relative to universal control. Universal control is a blood sample collected from an uninjected Cas9 transgenic mouse. Statistical analysis was performed using the non-parametric one-tailed Mann-Whitney U test. A p value ≤ 0.05 was considered significant (*P ≤ 0.05). Statistical source data are provided in .

    Journal: Nature cell biology

    Article Title: Synthetic immunomodulation with a CRISPR super-repressor in vivo

    doi: 10.1038/s41556-020-0563-3

    Figure Lengend Snippet: (A) Schematic of experiments demonstrating Cas9 transgenic mice treated with AAV1/Myd88 or AAV1/Mock at day 1, followed by a second administration of AAV1/Mock on day 21. (B) qRT-PCR analysis of Myd88 expression level in lung, blood, and bone marrow of Cas9 transgenic mice (N = 4 mice). Fold changes are relative to universal control. The bars represent the mean + S.E.M. (C) Schematic of the experiment. Cas9 nuclease transgenic mice were treated with AAV1-Myd88 or AAV1-Mock vectors via retro-orbital injection followed by a second and third injection of AAV9-PCSK9 vectors on day 7 and 21. (D) qRT-PCR analysis of Myd88 expression level in lung, blood, and bone marrow of Cas9 transgenic mice (N = 4 mice). The bars represent the mean + S.E.M. (Mock= Mock-HP1aKRAB, Myd88= Myd88-HP1aKRAB, PCSK9= PCSK9-HP1aKRAB). Fold changes are relative to universal control. Universal control is a blood sample collected from an uninjected Cas9 transgenic mouse. Statistical analysis was performed using the non-parametric one-tailed Mann-Whitney U test. A p value ≤ 0.05 was considered significant (*P ≤ 0.05). Statistical source data are provided in .

    Article Snippet: Plasma Pcsk9 protein levels were quantified by ELISA according to the manufacturer’s instructions (R&D Systems #MPC900).

    Techniques: Transgenic Assay, Quantitative RT-PCR, Expressing, Control, Injection, One-tailed Test, MANN-WHITNEY